Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis Abstract #364

Abstract content not available

Don’t be disappointed – you can look forward to seeing the full abstract from 10 March 2020 onwards.

Further abstracts you may be interested in

#144 Oxaliplatin-based chemotherapy in patients with advanced neuroendocrine carcinoma: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Francesca Spada
#2879 Lung Neuroendocrine Tumors: Experience of Medical Oncology Department of Hospital 1st November 1954 Oran
Introduction: Lung neuroendocrine tumors account for 25% of all neuroendocrine tumors. It is a heterogeneous group that meets morphological criteria; immunohistochemical and molecular; defining 4 groups: Typical and atypical carcinoid tumors, neuroendocrine carcinomas with large cell and small cells. Carcinoid syndrome is rare in these tumors and the treatment is based on surgery for localized forms and multimodal treatment for metastatic forms.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Hakima Kehili
#1026 Systemic Therapy in Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) and Ki Index 5-10%
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
#1125 Efficacy of PRRT in Metastatic Neuroendocrine Tumors; A Retrospective Large Single Institutional Study
Introduction: PRRT is a well-documented and well-established treatment for metastatic neuroendocrine tumours. However retrospective studies detailing the efficacy of PRRT are lacking.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Haamid Jan
Authors: Jan H, Wyld D, Burge M, ...
#2862 Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma
Introduction: The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD, PhD, Lecture Carmen Sorina Martin